fda approval of tirzepatide Diabetes Drug - Gets for Weight Loss The FDA approved Zepbound (tirzepatide)

Active Ingredient Semaglutide (Introductory GLP-1 Agonist) Total Strength per Vial Calibrated for 0.25mg and 0.5mg initial delivery Dose Classification Starter Phase & Early Titration Step 1 Primary Manufacturer Glenmark Pharmaceuticals Ltd Therapeutic Class Incretin Mimetic / Antidiabetic / Anti-Obesity Administration Route Subcutaneous Injection (Weekly calibrated dose) Supply Format 1 Multi-dose Vial / Pen System

Self-reported community protocols commonly describe once-daily dosing with on/off cycling, motivated partly by the absence of any long-term human safety data and partly by a community perception of diminishing returns or tolerance over continued use

Cortisol activates reward pathways for high-energy foods that can override GLP-1's appetite suppression mechanisms

Only support